Results 181 to 190 of about 738,044 (342)

Characterization of inflammatory pseudotumors in a large animal model of liver cancer

open access: yesAnimal Models and Experimental Medicine, EarlyView.
CT images in arterial and portal venous phases of liver lesions in Oncopig. Abstract Background The development of relevant and robust large animal models of hepatocellular carcinoma is needed to test new therapeutic strategies for this disease. Transgenic approaches hold promise in addressing this complex problem. One such model, the Oncopig, has been
Erik N. K. Cressman   +4 more
wiley   +1 more source

Kaposi sarcoma

open access: yesNature Reviews Disease Primers, 2019
Cecilia Taverna, Alessandro Franchi
semanticscholar   +2 more sources

3D Hydrogel Cell Cultures and Their Biomedical Applications

open access: yesAdvanced NanoBiomed Research, EarlyView.
The review highlights the advantages of hydrogel‐based 3D cell cultures over traditional 2D models. These hydrogels closely mimic natural cellular environments, improving research in tissue engineering, drug discovery, cancer studies, and neuroscience.
Tri Lan Thai   +7 more
wiley   +1 more source

Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

open access: yesThe Journal of the National Comprehensive Cancer Network, 2016
M. von Mehren   +29 more
semanticscholar   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

open access: yesJournal of Clinical Oncology, 2011
P. Robbins   +20 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy